Dalfampridine
Back to searchMolecule Structure
Scientific Name
Dalfampridine
Description of the Drug
Dalfampridine is a potassium channel blocker used for the improvement of motor function in patients with multiple sclerosis (MS).
Source: DrugBank Online – DrugBank.com. Retrieved 2023-03-10 from
http://www.drugbank.ca/drugs/DB06637
http://www.drugbank.ca/drugs/DB06637
Brand Name(s)
Ampyra, Ampyra Extended Release, Fampyra, Neurelan
Company Owner(s)
Micro Labs Ltd, Alkem Laboratories Ltd, Sun Pharmaceutical Industries Ltd, Rising Pharma Holding Inc, Actavis Laboratories Fl Inc, Acorda Therapeutics Inc, Aurobindo Pharma Ltd, Accord Healthcare Inc, Hikma Pharmaceuticals Usa Inc
Mechanism(s) Of Action
| Target Name | Target Type | Action Type | Target ChEMBL ID |
|---|---|---|---|
| Voltage-gated potassium channel | PROTEIN FAMILY | BLOCKER | CHEMBL2362996 |
Clinical Trial(s)
Unichem Links
| SureChEMBL | SCHEMBL53483 | |
| PharmGKB | PA166123389 | |
| DrugBank | DB06637 | |
| PubChem: Thomson Pharma | 15194226 | |
| PubChem | 1727 | |
| Mcule | MCULE-6604546217 | |
| NMRShiftDB | 10008866 | |
| LINCS | LSM-45521 | |
| Nikkaji | J270.956B | J1.568G |
| BindingDB | 10458 | |
| EPA CompTox Dashboard | DTXSID0023870 | |
| DrugCentral | 4163 | |
| Brenda | 13387 | |
| ChemicalBook | CB9853687 | |
| Guide to Pharmacology | 2416 | |
| rxnorm | AMPYRA | DALFAMPRIDINE |
| PubChem: Drugs of the Future | 12014686 | |
| KEGG Ligand | C13728 | |
| ChEBI | 34385 | |
| ZINC | ZINC000000599985 |
